634 related articles for article (PubMed ID: 29682980)
41. Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence.
Liu Q; Zhu H; Dong J; Li H; Zhang H
Int J Clin Exp Pathol; 2015; 8(10):13059-66. PubMed ID: 26722501
[TBL] [Abstract][Full Text] [Related]
42. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
43. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
44. Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion.
Kouvidi E; Stratigi A; Batsali A; Mavroudi I; Mastrodemou S; Ximeri M; Papadaki HA; Pontikoglou CG
Leuk Res; 2016 Apr; 43():24-32. PubMed ID: 26930455
[TBL] [Abstract][Full Text] [Related]
45. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
[TBL] [Abstract][Full Text] [Related]
46. Bone marrow mesenchymal stem cells in patients with beta thalassemia major: molecular analysis with attenuated total reflection-Fourier transform infrared spectroscopy study as a novel method.
Aksoy C; Guliyev A; Kilic E; Uckan D; Severcan F
Stem Cells Dev; 2012 Jul; 21(11):2000-11. PubMed ID: 22214206
[TBL] [Abstract][Full Text] [Related]
47. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
48. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
[TBL] [Abstract][Full Text] [Related]
49. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.
Geyh S; Oz S; Cadeddu RP; Fröbel J; Brückner B; Kündgen A; Fenk R; Bruns I; Zilkens C; Hermsen D; Gattermann N; Kobbe G; Germing U; Lyko F; Haas R; Schroeder T
Leukemia; 2013 Sep; 27(9):1841-51. PubMed ID: 23797473
[TBL] [Abstract][Full Text] [Related]
50. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
51. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients.
Han Q; Sun Z; Liu L; Chen B; Cao Y; Li K; Zhao RC
Leuk Res; 2007 Nov; 31(11):1469-78. PubMed ID: 17360037
[TBL] [Abstract][Full Text] [Related]
52. MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.
Giallongo C; Dulcamare I; Giallongo S; Duminuco A; Pieragostino D; Cufaro MC; Amorini AM; Lazzarino G; Romano A; Parrinello N; Di Rosa M; Broggi G; Caltabiano R; Caraglia M; Scrima M; Pasquale LS; Tathode MS; Li Volti G; Motterlini R; Di Raimondo F; Tibullo D; Palumbo GA
Cell Death Dis; 2023 Oct; 14(10):686. PubMed ID: 37852977
[TBL] [Abstract][Full Text] [Related]
53. In Vitro Insights Into the Influence of Marrow Mesodermal/Mesenchymal Progenitor Cells on Acute Myelogenous Leukemia and Myelodysplastic Syndromes.
Liesveld J; Galipeau J
Stem Cells; 2023 Sep; 41(9):823-836. PubMed ID: 37348128
[TBL] [Abstract][Full Text] [Related]
54. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.
Medyouf H; Mossner M; Jann JC; Nolte F; Raffel S; Herrmann C; Lier A; Eisen C; Nowak V; Zens B; Müdder K; Klein C; Obländer J; Fey S; Vogler J; Fabarius A; Riedl E; Roehl H; Kohlmann A; Staller M; Haferlach C; Müller N; John T; Platzbecker U; Metzgeroth G; Hofmann WK; Trumpp A; Nowak D
Cell Stem Cell; 2014 Jun; 14(6):824-37. PubMed ID: 24704494
[TBL] [Abstract][Full Text] [Related]
55. An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program.
Gnani D; Crippa S; Della Volpe L; Rossella V; Conti A; Lettera E; Rivis S; Ometti M; Fraschini G; Bernardo ME; Di Micco R
Aging Cell; 2019 Jun; 18(3):e12933. PubMed ID: 30828977
[TBL] [Abstract][Full Text] [Related]
56. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.
Flores-Figueroa E; Arana-Trejo RM; Gutiérrez-Espíndola G; Pérez-Cabrera A; Mayani H
Leuk Res; 2005 Feb; 29(2):215-24. PubMed ID: 15607371
[TBL] [Abstract][Full Text] [Related]
57. MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis.
Hayashi Y; Kawabata KC; Tanaka Y; Uehara Y; Mabuchi Y; Murakami K; Nishiyama A; Kiryu S; Yoshioka Y; Ota Y; Sugiyama T; Mikami K; Tamura M; Fukushima T; Asada S; Takeda R; Kunisaki Y; Fukuyama T; Yokoyama K; Uchida T; Hagihara M; Ohno N; Usuki K; Tojo A; Katayama Y; Goyama S; Arai F; Tamura T; Nagasawa T; Ochiya T; Inoue D; Kitamura T
Cell Rep; 2022 May; 39(6):110805. PubMed ID: 35545056
[TBL] [Abstract][Full Text] [Related]
58. Myelodysplasia is in the niche: novel concepts and emerging therapies.
Bulycheva E; Rauner M; Medyouf H; Theurl I; Bornhäuser M; Hofbauer LC; Platzbecker U
Leukemia; 2015 Feb; 29(2):259-68. PubMed ID: 25394715
[TBL] [Abstract][Full Text] [Related]
59. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
60.
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
